About RHEI

Overview

RHEI Pharmaceuticals HK Ltd (RHEI) is a global pharmaceuticals business development company, with a special focus on bringing core medicines from the U.S., Europe and Japan, into the fast-growing Chinese marketplace. RHEI in-licenses approved and late stage pharmaceutical products from these reference countries, and applies its development and regulatory expertise to bring these important therapies to China. RHEI’s internal capabilities encompass business development, regulatory approval and clinical development– combining a western approach to pharmaceuticals with Chinese professionals that are highly experienced in the region. They use their development capabilities and network of preferred commercial partners to help other pharmaceutical companies introduce their products into specific niche markets, such as the European institutional healthcare market and the Chinese hospital market.

Currently, RHEI is in the process of bringing several products in its pipeline through the clinical development and regulatory steps essential to entering these products in the Chinese market. As from 2010 on, during a 2nd phase of expansion, RHEI started accelerating its commercial activities, in part through preferred distribution partnerships. Later on, in a 3rd phase, the company will focus on directly controlling the manufacturing aspects of its product portfolio. RHEI has particular expertise in the areas of oncology, women’s health, infectious diseases and dermatology. RHEI applies its unique offering to branded pharmaceuticals through its close relationship with selected preferred commercial partners. RHEI is headquartered in Hong Kong and has operations in the US and China.

NEWSFLASH: Access Pharmaceuticals receives final marketing approval from SFDA of China for Mugard